Intercure Ltd. (INCR)
INCR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1857030/000149315226020743/0001493152-26-020743-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31. Converted from ILS at 3.2107 per USD (today's ECB or Federal Reserve reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | INCR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Israel |
| IPO year | Not reported by the screener |
| SEC CIK | 0001857030 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Israel |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $84.2M |
| Net income | -$11.1M |
| Operating income | -$8.5M |
| Net margin | -13.2% |
| Operating margin | -10.1% |
| Revenue growth | +13.1% |
| Cash | $14.5M |
| Total assets | $215.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.6× |
Reported in ILS; shown in US dollars.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-04-30 |
| Cash and burn | 46.5M ILS cash; operating cash flow 4.2M ILS a quarter. | Report 2025-12-31 |
| Shares outstanding | 10,936,267 (2025-12-31); 47,162,713 a year earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | 1; latest 1-for-5 on 2026-08-24 | Source 2026-08-24 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Somekh Chaikin, Tel Aviv, Israel | PCAOB Form AP 2026-05-31 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | 270.2M ILS | -35.7M ILS | 16.8M ILS | 46.5M ILS | 148.0M ILS | 270.2M ILS | 20-F 2026-04-30 |
| FY 2024 2024-12-31 | 238.8M ILS | -67.8M ILS | -66.9M ILS | 78.3M ILS | 183.0M ILS | 238.8M ILS | 20-F 2025-05-01 |
| FY 2023 2023-12-31 | 355.6M ILS | -62.0M ILS | -53.6M ILS | 101.1M ILS | 170.0M ILS | 355.6M ILS | 20-F 2025-05-01 |
| FY 2022 2022-12-31 | 388.7M ILS | 44.8M ILS | 51.3M ILS | 232.6M ILS | 227.0M ILS | 388.7M ILS | 20-F 2025-05-01 |
| FY 2021 2021-12-31 | 219.7M ILS | 4.7M ILS | 30.1M ILS | 196.2M ILS | 82.4M ILS | 219.7M ILS | 20-F 2024-05-01 |
| FY 2020 2020-12-31 | 65.0M ILS | -37.2M ILS | 7.9M ILS | 37.9M ILS | 745K ILS | 65.0M ILS | 20-F 2023-05-01 |
| FY 2019 2019-12-31 | 8.9M ILS | -5.9M ILS | -11.6M ILS | 27.3M ILS | No debt tags | 8.9M ILS | 20-F 2022-04-28 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in ILS.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | POS AM | 2022-06-23 |
| Latest annual report | 20-F | 2026-04-30 |
| Latest quarterly / interim | 6-K | 2026-09-08 |
Source: SEC EDGAR submissions feed, 119 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +9.2% |
| 1 month | -24.7% |
| 3 months | -18.1% |
| Year to date | -16.7% |
| 1 year | -44.7% |
| From 52-week high | -47.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AZR | Azora Therapeutics Inc. | $3.81 | -6.85% | $54.4M |
| CING | Cingulate Inc. | $3.75 | -12.79% | $54.5M |
| XLO | Xilio Therapeutics Inc. | $7.70 | -3.08% | $54.4M |
| HRTX | Heron Therapeutics Inc. | $0.2843 | -8.44% | $54.1M |
| VRCA | Verrica Pharmaceuticals Inc. | $3.20 | -10.11% | $55.0M |
| SPRO | Spero Therapeutics Inc. | $0.9464 | -5.35% | $55.1M |
| TNXP | Tonix Pharmaceuticals Holding Corp. | $2.88 | -4.32% | $56.0M |
| CLNN | Clene Inc. | $3.66 | -6.63% | $52.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier